Lab guide · Comparisons
CJC-1295 with DAC vs Without DAC: Two Different Molecules Under One Name
CJC-1295 with DAC vs without DAC is a comparison between a 30-residue GHRH analogue carrying an albumin-binding linker and the 29-residue peptide it is built on. The two share a core sequence but differ in structure, mass and duration of action by orders of magnitude. This guide sets out the seven differences and explains why published data for one cannot be assigned to the other.
Key takeaways
- CJC-1295 without DAC is Mod GRF(1-29), a 29-residue GHRH analogue with four substitutions; the DAC form adds a lysine carrying a maleimide group that binds albumin.
- The DAC form has a reported half-life of 5.8-8.1 days in a 2006 human study; the no-DAC form is reported at about 30 minutes in supplier data.
- The 2006 human data concern the DAC form, so they cannot be read across to the no-DAC peptide.
- The two have different masses (about 3647 and 3368 g/mol), so intact-mass testing tells them apart.
CJC-1295 with DAC vs without DAC at a glance
| # | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|---|
| 1 | Structure | Mod GRF(1-29) plus Lys30 with an epsilon-maleimidopropionyl group (30 residues) | [D-Ala2, Gln8, Ala15, Leu27]-GHRH(1-29) amide (29 residues) |
| 2 | Formula and mass | C165H269N47O46, about 3647.2 g/mol | C152H252N44O42, about 3367.9 g/mol |
| 3 | CAS number | 446262-90-4 | 863288-34-0 |
| 4 | Persistence mechanism | Maleimide forms a thioether bond with Cys34 of serum albumin | None; relies on four substitutions that improve DPP-IV stability |
| 5 | Half-life | 5.8-8.1 days (human study) | About 30 minutes (supplier data) |
| 6 | Human data | 2006 randomised placebo-controlled studies in healthy adults | No equivalent published study identified in the sources reviewed |
| 7 | Analytical watch-point | Intact maleimide required; hydrolysis adds 18 Da | No linker to hydrolyse; ordinary peptide degradation routes |
Research use only. This comparison summarises published laboratory and clinical-pharmacology research. Baltic Peptides supplies CJC-1295 with DAC for in-vitro and preclinical research by qualified researchers; they are not medicines and are not for human or veterinary use.
The shared core
Both forms use the Mod GRF(1-29) sequence, the first 29 residues of human GHRH with D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. These substitutions are designed to stabilise the peptide, as explained in What is CJC-1295 No DAC. Jette et al. (2005) reported that albumin conjugates of hGRF(1-29) showed enhanced in vitro stability against dipeptidyl peptidase-IV and were active in a GH secretion assay in rat pituitary cells.
What the DAC adds
CJC-1295 with DAC is a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus (Jette et al. (2005)). In rats, a CJC-1295 immunoreactive species was found on the band corresponding to serum albumin within 15 minutes of injection and remained in circulation beyond 24 hours, and the compound was present in plasma beyond 72 hours. The best compound showed a four-fold increase in GH area under the curve over 2 hours compared with hGRF(1-29).
What the human study measured
Teichman et al. (2006) ran two randomised, placebo-controlled, double-blind ascending-dose studies in healthy adults of 21 to 61 years. After a single injection of CJC-1295 there were dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold for 6 days or more and in IGF-I of 1.5- to 3-fold for 9-11 days, with an estimated half-life of 5.8-8.1 days. After multiple doses, IGF-I remained above baseline for up to 28 days, and no serious adverse reactions were reported.
This study concerns the DAC form, which is the compound the early clinical literature calls CJC-1295. Those results do not describe the no-DAC peptide.
Sustained versus pulsatile stimulation
A short-lived analogue gives a brief receptor signal, while an albumin-bound one produces prolonged receptor exposure. In the Baltic Peptides product description, the two forms are framed as answering different research questions: sustained receptor stimulation and its adaptation for the DAC form, and pulsatile stimulation for the no-DAC form. The comparison itself, not either compound alone, is the experimental variable in that design.
Why mass testing matters here
The two forms differ by about 280 g/mol, so intact-mass analysis separates them immediately. The DAC form also has a specific weak point: if the maleimide hydrolyses to its ring-opened form, the mass rises by 18 Da and albumin binding is lost, so a DAC vial can pass a purity test and still behave like a short-acting peptide. See peptide mass spectrometry and peptide half-life extension for how albumin binding compares with other strategies.
Limits and caveats
- The no-DAC half-life comes from supplier data, not a primary study retrieved here.
- The Baltic Peptides product page states that development of CJC-1295 was halted in 2006; that statement was not independently verified here.
- Neither form is approved by EMA or FDA, and GHRH analogues are on the WADA Prohibited List.
- Rat and cell data cannot be assumed to apply to other systems.
Sources and further reading
- Teichman S.L. et al. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 91(3):799-805. PubMed
- Jette L. et al. (2005). hGRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146(7):3052-3058. PubMed
- Baltic Peptides product page, CJC-1295 with DAC (formula, mass and CAS number). balticpeptides.com
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article explains analytical and chemical concepts and is for educational purposes only.
FAQ
Common questions
What is the difference between CJC-1295 with DAC and without DAC?
What does DAC stand for?
How long does each form last?
Is CJC-1295 without DAC the same as Mod GRF 1-29?
Do the human CJC-1295 studies apply to the no-DAC peptide?
How can the two forms be told apart in testing?
Why does maleimide hydrolysis matter for the DAC form?
Keep reading
Related reading
What is CJC-1295 with DAC?
Structure, albumin binding and the published data.
What is CJC-1295 No DAC?
The four-substitution GHRH(1-29) analogue.
GHRH vs GHRP
Two receptor classes that control GH release.
Research-grade CJC-1295 with DAC, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
